|
1
|
Lafaro KJ, Demirjian AN and Pawlik TM:
Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am.
24:1–17. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fan Y and Zong WX: PARP Activation and
Necrotic Cell Death. Necrotic Cell Death. Shen HM and Vandenabeele
P: New York, NY: Springer; pp. 163–175. 2014, View Article : Google Scholar
|
|
3
|
Speers C, Feng FY and Pierce LJ: PARP-1
inhibitors and radiotherapy sensitivity: Future prospects for
therapy? Breast Cancer Management. 3:281–296. 2014. View Article : Google Scholar
|
|
4
|
Somlo G, Frankel P, Luu T, Ma C, Arun B,
Garcia A, Cigler T, Harvey HA, Sparano JA, et al: Phase II trial of
single agent PARP inhibitor ABT-888 (veliparib [vel]) followed by
postprogression therapy of vel with carboplatin (carb) in patients
(pts) with stage BRCA-associated metastatic breast caner (MBC):
California Cancer Consortium trial PHII-96. J Clin Oncol.
32:(suppl). S10212014.
|
|
5
|
Stewart E, Goshorn R, Bradley C, Griffiths
LM, Benavente C, Twarog NR, Miller GM, Caufield W, Freeman BB III,
Bahrami A, et al: Targeting the DNA repair pathway in ewing
sarcoma. Cell Rep. 9:829–841. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cipak L and Jantova S: PARP-1 inhibitors:
A novel genetically specific agents for cancer therapy. Neoplasma.
57:401–405. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ibrahim YH, Garcia-Garcia C, Serra V, He
L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J,
et al: PI3K inhibition impairs BRCA1/2 expression and sensitizes
BRCA-proficient triple-negative breast cancer to PARP inhibition.
Cancer Discov. 2:1036–1047. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou X, Huang ZY, Chen XP and Huang SH:
Suppressive effect of poly (ADP-ribose)polymerase-1 inhibitor PJ34
on human hepatoma cell line HepG2. World Chinese Journal of
Digestology. 15:1806–1809. 2007.(In Chinese).
|
|
9
|
Milella M, Falcone I, Conciatori F, Incani
Cesta U, Del Curatolo A, Inzerilli N, Nuzzo CM, Vaccaro V, Vari S,
Cognetti F and Ciuffreda L: PTEN: Multiple functions in human
malignant tumors. Front Oncol. 5:242015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Banik D, Netherby CS, Bogner PN and Abrams
SI: MMP3-mediated tumor progression is controlled transcriptionally
by a novel IRF8-MMP3 interaction. Oncotarget. 6:15164–15179. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Domagala P, Huzarski T, Lubinski J, Gugala
K and Domagala W: PARP-1 expression in breast cancer including
BRCA1-associated, triple negative and basal-like tumors: Possible
implications for PARP-1 inhibitor therapy. Breast Cancer Res Treat.
127:861–869. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
de Lope CR, Tremosini S, Forner A, Reig M
and Bruix J: Management of HCC. J Hepatol. 56:(Suppl 1). S75–S87.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Golia B, Singh HR and Timinszky G:
Poly-ADP-ribosylation signaling during DNA damage repair. Front
Biosci (Landmark Ed). 20:440–457. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang X, Ndawula C Jr, Zhou H, Gong X and
Jin J: JF-305, a pancreatic cancer cell line is highly sensitive to
the PARP inhibitor olaparib. Oncol Lett. 9:757–761. 2015.PubMed/NCBI
|
|
15
|
Muñoz-Gámez JA, Viota López J, Barrientos
A, Carazo Á, Sanjuán-Nuñez L, Quiles-Perez R, Muñoz-de-Rueda P,
Delgado Á, Ruiz-Extremera Á and Salmerón J: Synergistic
cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888
and temozolomide in dual-drug targeted magnetic nanoparticles.
Liver Int. 35:1430–1441. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chuang HC, Kapuriya N, Kulp SK, Chen CS
and Shapiro CL: Differential anti-proliferative activities of
poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative
breast cancer cells. Breast Cancer Res Treat. 134:649–659. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fiandalo MV and Kyprianou N: Caspase
control: Protagonists of cancer cell apoptosis. Exp Oncol.
34:165–175. 2012.PubMed/NCBI
|
|
18
|
Forster MD, Dedes KJ, Sandhu S, Frentzas
S, Kristeleit R, Ashworth A, Poole CJ, Weigelt B, Kaye SB and
Molife LR: Treatment with olaparib in a patient with PTEN-deficient
endometrioid endometrial cancer. Nat Rev Clin Oncol. 8:302–306.
2011. View Article : Google Scholar : PubMed/NCBI
|
